
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>The San Diego Consensus for Laryngopharyngeal Symptoms and Laryngopharyngeal Reflux Disease</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>The San Diego Consensus for Laryngopharyngeal Symptoms and Laryngopharyngeal Reflux Disease</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: American Journal of Gastroenterology, 2026 (Vol. 121)</li>
<li style="margin-left: 0px;">Topic: Laryngopharyngeal Symptoms (LPS) and Laryngopharyngeal Reflux Disease (LPRD)</li>
<li style="margin-left: 0px;">Author(s): Yadlapati et al. (28-member international interdisciplinary working group)</li>
</ul>
<details><summary><strong>1. Introduction and Background</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>1.1 Clinical Context and Problem Statement</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Laryngopharyngeal reflux (LPR) is widely used in clinical practice as descriptor for proximal esophageal and aerodigestive symptoms, yet lacks finite diagnostic criteria</li>
<li style="margin-left: 0px;">LPR accounts for up to <strong>10%</strong> of otolaryngology and gastroenterology visits</li>
<li style="margin-left: 0px;">Healthcare costs reported <strong>5.4 times higher</strong> than for gastroesophageal reflux disease (GERD), primarily from prolonged acid suppression trials and diagnostic uncertainty</li>
<li style="margin-left: 0px;">Significant negative impact on quality of life: higher rates of <strong>anxiety, depression</strong>, and impaired social functioning, regardless of diagnosis method</li>
<li style="margin-left: 0px;">Life-threatening long-term sequelae (e.g., cancer) are infrequent</li>
</ul>
</div></details>
<details><summary><strong>1.2 Evidence Gap</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Many symptoms attributed to retrograde flow of gastric contents to upper aerodigestive tract, yet few LPS are directly linked to this mechanism</li>
<li style="margin-left: 0px;">Evidence of GERD is not uniformly present despite LPR being categorized as extraesophageal GERD</li>
<li style="margin-left: 0px;">As many as <strong>60% of patients diagnosed with LPR</strong> have normal objective ambulatory reflux monitoring studies</li>
<li style="margin-left: 0px;">This challenges the theory that reflux is mechanism underlying most presentations → objective evidence of LPR disease (LPRD) is low</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>2. Methods</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>2.1 Working Group Composition</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>28-member international interdisciplinary working group</strong>:</li>
<li style="margin-left: 20px;">12 esophageal expert gastroenterologists/physiologists (GIs)</li>
<li style="margin-left: 20px;">9 laryngologists (ENTs)</li>
<li style="margin-left: 20px;">6 speech-language pathologists (SLPs)</li>
<li style="margin-left: 20px;">1 clinical psychologist</li>
<li style="margin-left: 0px;">Timeline: 1-year initiative (October 2023 to October 2024)</li>
<li style="margin-left: 0px;">Meetings: 5 virtual, 2 hybrid (Hong Kong May 2024, Austria October 2024)</li>
</ul>
</div></details>
<details><summary><strong>2.2 Subgroups and Process</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Six subgroups</strong>: (i) definition/terminology, (ii) initial diagnostic evaluation, (iii) reflux monitoring, (iv) therapeutic trial, (v) behavioral factors/therapy, (vi) risk stratification</li>
<li style="margin-left: 0px;">Each subgroup led by 2 interdisciplinary co-chairs → literature review, statement development, evidence presentation</li>
</ul>
</div></details>
<details><summary><strong>2.3 Voting Methodology</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">RAND Appropriateness Method: formally validated methodology for determining statement appropriateness</li>
<li style="margin-left: 0px;">Independent electronic voting via UC San Diego Research Electronic Database Capture</li>
<li style="margin-left: 0px;">Statements ranked as appropriate with <strong>≥80% agreement</strong> included as final recommendations</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3. Definition and Terminology</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>3.1 Laryngopharyngeal Symptoms (LPS)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Definition</strong>: Chronic and frequent throat and upper airway symptoms that have potential to be induced by retrograde flow of gastric content to the upper esophagus, pharynx, and larynx</li>
<li style="margin-left: 0px;"><strong>Frequency criterion</strong>: Symptoms occurring at least <strong>twice weekly</strong></li>
<li style="margin-left: 0px;"><strong>Duration criterion</strong>: Present for <strong>8 weeks or more</strong></li>
</ul>
<details><summary><strong>LPS Symptoms (with agreement levels):</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Cough</strong> (89% agreement)</li>
<li style="margin-left: 0px;"><strong>Regurgitation</strong> (89%)</li>
<li style="margin-left: 0px;"><strong>Throat pain/sore throat</strong> (89%)</li>
<li style="margin-left: 0px;"><strong>Throat clearing</strong> (86%)</li>
<li style="margin-left: 0px;"><strong>Excess phlegm</strong> (82%)</li>
<li style="margin-left: 0px;"><strong>Hoarseness/voice change</strong> (80%)</li>
</ul>
</div></details>
<details><summary><strong>Important Notes:</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Multiple mechanisms can lead to LPS; term does <strong>not implicate reflux</strong> as etiology</li>
<li style="margin-left: 0px;">All aforementioned symptoms are poorly specific for true LPRD → <strong>presence of LPS does NOT equate to LPRD</strong></li>
<li style="margin-left: 0px;">Globus is important symptom warranting evaluation (often negative predictor of reflux physiology)</li>
<li style="margin-left: 0px;">Symptoms NOT meeting agreement: tongue burning, nasal burning, postnasal drip, halitosis, belching, dysphagia</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3.2 Laryngopharyngeal Reflux Disease (LPRD)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Definition</strong>: Requires chronic troublesome LPS + objective evidence supporting relationship between symptoms and gastroesophageal reflux</li>
<li style="margin-left: 0px;">Prevalence: While LPS is high, proportion with objective LPRD on diagnostic evaluation is low (~<strong>35%</strong>)</li>
<li style="margin-left: 0px;"><strong>Objective evidence required</strong>: LPS AND either:</li>
<li style="margin-left: 20px;">(i) Concurrent esophageal reflux-like symptoms with LPS that respond to trial of anti-reflux therapy, OR</li>
<li style="margin-left: 20px;">(ii) Diagnostic evidence of gastroesophageal reflux on upper GI endoscopy or ambulatory reflux monitoring</li>
</ul>
</div></details>
<details><summary><strong>3.3 Symptom Categorization</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">LPS can occur <strong>with</strong> esophageal reflux symptoms (heartburn, regurgitation, chest pain) OR</li>
<li style="margin-left: 0px;">LPS can occur <strong>independently</strong> (isolated LPS)</li>
<li style="margin-left: 0px;">Diagnostic and management algorithms differ based on this distinction</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4. Diagnostic Evaluation: Role of Laryngoscopy</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>4.1 Key Principles</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Laryngoscopy is necessary</strong> in evaluating LPS primarily to rule out alternate laryngeal pathologies including neoplasia</li>
<li style="margin-left: 0px;"><strong>LPRD cannot be diagnosed based on laryngoscopy findings alone</strong></li>
<li style="margin-left: 0px;">Primary role: evaluate for other non-reflux related otolaryngologic processes including malignancy</li>
</ul>
</div></details>
<details><summary><strong>4.2 Laryngoscopic Findings Limitations</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Findings on white light examination (infraglottic edema, interarytenoid mucosal hypertrophy, erythematous changes, postcricoid mucosal edema) are <strong>nonspecific</strong> for LPRD</li>
<li style="margin-left: 0px;">May result from other causes of laryngeal inflammation or be found in <strong>healthy, asymptomatic individuals</strong></li>
<li style="margin-left: 0px;">LPRD often erroneously assumed to cause LPS despite changes in other vibratory parameters (symmetry, amplitude, mucosal wave, glottic closure) visualized by stroboscopy</li>
</ul>
</div></details>
<details><summary><strong>4.3 Clinical Recommendations</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Laryngoscopic finding instruments (Reflux Finding Score, Reflux Sign Assessment) <strong>should NOT be used to diagnose LPRD</strong> due to suboptimal specificity</li>
<li style="margin-left: 0px;">When LPS includes hoarseness not explained by white light flexible laryngoscopy → <strong>videostroboscopic examination</strong> should be performed to evaluate for other etiologies</li>
<li style="margin-left: 0px;">Benign vocal fold lesions, keratotic/premalignant dysplastic/malignant lesions can present with dysphonia, chronic throat clearing, globus sensation → often ascribed to LPRD</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>5. Symptom Characterization and Medical Trials</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>5.1 Initial Assessment Algorithm</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Presence of concurrent esophageal reflux symptoms vs. absence (isolated LPS) should be determined early</li>
<li style="margin-left: 0px;">Algorithms differ for: (i) LPS with concurrent esophageal symptoms vs. (ii) isolated LPS</li>
</ul>
</div></details>
<details><summary><strong>5.2 Empiric Antireflux Trials</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>When appropriate</strong>: LPS with concurrent esophageal reflux symptoms</li>
<li style="margin-left: 0px;"><strong>Trial components</strong>:</li>
<li style="margin-left: 20px;">PPI (omeprazole 20 mg) <strong>twice daily for 3 months</strong></li>
<li style="margin-left: 20px;">May include alginate therapy (4 times daily: after meals and before bedtime)</li>
<li style="margin-left: 20px;">Dietary and lifestyle modifications</li>
<li style="margin-left: 0px;">Alginate therapy may augment acid suppression effectiveness</li>
</ul>
</div></details>
<details><summary><strong>5.3 Isolated LPS Management</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Acid-reducing medications <strong>NOT recommended as first-line therapy</strong> without demonstration of diagnostic evidence of reflux</li>
<li style="margin-left: 0px;">Esophageal evaluation recommended instead of empiric medical trials</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>6. Upper Gastrointestinal Endoscopy</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>6.1 Conclusive Evidence of GERD</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Los Angeles grades B, C, D esophagitis</strong></li>
<li style="margin-left: 0px;"><strong>Biopsy-proven Barrett&#x27;s esophagus</strong></li>
<li style="margin-left: 0px;">Using Lyon Consensus paradigms, these findings establish GERD presence when encountered off acid suppressive therapy</li>
</ul>
</div></details>
<details><summary><strong>6.2 Supportive Findings</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Disrupted esophagogastric junction (e.g., hiatal hernia, Hill grade)</li>
<li style="margin-left: 0px;">Recent multicenter study: up to <strong>47%</strong> of patients presenting with LPS demonstrated erosive findings and/or hiatal hernia</li>
<li style="margin-left: 0px;">Findings may be present in both patients with esophageal symptoms AND those with isolated LPS</li>
</ul>
</div></details>
<details><summary><strong>6.3 Transnasal Esophagoscopy</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Office-based transnasal esophagoscopy can screen for erosive esophagitis and Barrett&#x27;s esophagus</li>
<li style="margin-left: 0px;">Shown to be similarly diagnostic compared with standard upper endoscopy</li>
<li style="margin-left: 0px;">Should be performed by providers with specialized training in esophageal endoscopy</li>
</ul>
</div></details>
<details><summary><strong>6.4 Cervical Inlet Patch</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Area of heterotopic gastric mucosa in proximal esophagus</li>
<li style="margin-left: 0px;">May secrete acid, mucus, or pepsin; can be associated with LPS and globus</li>
<li style="margin-left: 0px;">Ablation shown to reduce LPS in small case series</li>
<li style="margin-left: 0px;">Panel could NOT reach agreement on value of identifying/treating inlet patch (limited evidence)</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>7. Ambulatory Reflux Monitoring for Evaluation of LPS</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>7.1 Role and Key Principles</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Ambulatory reflux monitoring is the reference standard for diagnosing LPRD</strong></li>
<li style="margin-left: 0px;">Essential evidence before endoscopic or surgical antireflux interventions (invasive, irreversible, expensive)</li>
<li style="margin-left: 0px;">In patients with isolated LPS → lower pretest likelihood of GERD → early ambulatory reflux monitoring helps confirm or exclude GERD and personalize management</li>
<li style="margin-left: 0px;">In absence of endoscopic evidence of GERD → ambulatory reflux monitoring is reference standard for diagnosing LPRD</li>
</ul>
</div></details>
<details><summary><strong>7.2 Clinical Indications</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Next step</strong> in evaluating patients with LPS and concurrent esophageal symptoms who do not respond to empiric trials of antisecretory and/or alginate therapy, in absence of endoscopic evidence of GERD</li>
<li style="margin-left: 0px;">Should be considered in patients requiring <strong>long-term medical antireflux management</strong> → primarily to confirm pathologic reflux burden before long-term acid suppressive therapy</li>
<li style="margin-left: 0px;">Diagnostic evaluation of whether LPS are potentially related to reflux first requires determining whether pathologic gastroesophageal reflux is present</li>
<li style="margin-left: 0px;">Objective evidence of GERD on reflux testing in patients with LPS does NOT necessarily implicate reflux as causative of patient&#x27;s LPS</li>
<li style="margin-left: 0px;"><strong>Absence of GERD</strong> makes it unlikely that GERD is mechanism underlying LPS or that antireflux therapies will improve LPS</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>8. Modality and Interpretation of Ambulatory Reflux Monitoring</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>8.1 Testing Requirements</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Performed off acid suppression therapy</strong> in patients with unproven GERD</li>
<li style="margin-left: 0px;">Two primary modalities: 24-hour multichannel intraluminal pH-impedance monitoring AND prolonged wireless pH monitoring</li>
<li style="margin-left: 0px;">Both provide measurement of <strong>distal esophageal acid exposure time (AET)</strong></li>
<li style="margin-left: 0px;">Each modality provides differing capabilities and value → <strong>not mutually exclusive</strong></li>
</ul>
</div></details>
<details><summary><strong>8.2 pH-Impedance Monitoring</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Offers added ability to detect proximal reflux events with greater detail depending on probe placement and catheter configuration</li>
<li style="margin-left: 0px;">Particularly important since hypopharyngeal events may be more likely to contribute to LPS</li>
<li style="margin-left: 0px;">Superior to traditional esophageal pH monitoring in detecting proximal esophageal reflux events</li>
<li style="margin-left: 0px;"><strong>Hypopharyngeal reflux events</strong> demonstrated using dual channel or hypopharyngeal-esophageal multichannel intraluminal impedance with dual pH (HEMII-pH) catheters</li>
<li style="margin-left: 0px;">These events often occur as <strong>weakly-acidic or nonacidic reflux episodes</strong> that may predict treatment outcomes</li>
<li style="margin-left: 0px;">HEMII-pH catheter configurations identified pharyngeal reflux events in <strong>81% of 42 patients</strong> with suspected reflux-mediated pathology in LPS</li>
<li style="margin-left: 0px;">Includes <strong>72% who tested negative for esophageal-only criteria</strong> → highlights diagnostic gap addressed by standard dual-channel pH-impedance monitoring</li>
<li style="margin-left: 0px;">Panel could NOT reach agreement for thresholds of &gt;80 esophageal reflux events and &gt;10 hypopharyngeal events to be considered abnormal → further research needed</li>
</ul>
</div></details>
<details><summary><strong>8.3 Prolonged Wireless pH Monitoring</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Uses single pH sensor positioned in distal esophagus during sedated endoscopy → wirelessly transmits data to recorder for up to <strong>96 hours</strong></li>
<li style="margin-left: 0px;">Major advantage: capacity to monitor for prolonged periods and capture variability rather than relying solely on 24-hour snapshot</li>
<li style="margin-left: 0px;">Significant day-to-day variability in esophageal acid exposure</li>
<li style="margin-left: 0px;">When goal is highest diagnostic accuracy in demonstrating pathologic GERD → <strong>96-hour prolonged wireless pH monitoring outperforms</strong> 24-hour or 48-hour studies</li>
<li style="margin-left: 0px;">Double-blind, multicenter trial of 100 patients with troublesome esophageal reflux symptoms and inadequate PPI response:</li>
<li style="margin-left: 20px;">Participants with <strong>0 days of elevated AET</strong> had <strong>10 times increased odds</strong> of stopping PPI compared to those with 4 days of elevated AET</li>
<li style="margin-left: 20px;">When AET elevated on <strong>2 or more days</strong>, odds ratio for predicting need to continue PPI treatment was <strong>5.3</strong> (95% CI 2.19–13.44)</li>
<li style="margin-left: 0px;">Recent guidance positions 96-hour wireless pH testing off antisecretory therapy as <strong>preferred test for unproven GERD</strong></li>
<li style="margin-left: 0px;">Prolonged pH monitoring provides higher diagnostic yield of pathologic GERD in patients with LPS</li>
<li style="margin-left: 0px;">Recent multicenter international study of 813 patients: diagnostic yield of GERD in patients referred for LPS was <strong>50% on prolonged wireless pH monitoring vs 27%</strong> on 24-hour pH impedance monitoring (including HEMII-pH)</li>
</ul>
</div></details>
<details><summary><strong>8.4 Interpretation Criteria</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Definitive Abnormal (Proven GERD):</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Distal esophageal AET &gt;6.0%</strong> on ambulatory reflux monitoring → meets criteria for proven GERD</li>
<li style="margin-left: 0px;">On 96-hour wireless pH: AET &gt;6.0% on <strong>2 or more days</strong> of monitoring</li>
</ul>
</div></details>
<details><summary><strong>Physiologic (Exclusionary):</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Distal esophageal AET &lt;4.0%</strong> is considered physiologic</li>
<li style="margin-left: 0px;">On 96-hour prolonged wireless pH: AET &lt;4.0% on <strong>all 4 days</strong> predicts low likelihood of symptom response with antisecretory therapy</li>
<li style="margin-left: 0px;">AET &gt;4.0% on 1 or more day of monitoring → supportive but not conclusive</li>
</ul>
</div></details>
<details><summary><strong>Positive Symptom-Reflux Association:</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Strengthens diagnostic confidence for LPRD</li>
<li style="margin-left: 0px;">Particularly valuable on 96-hour wireless pH monitoring</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>8.5 Oropharyngeal pH Monitoring Limitations</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Introduced as minimally invasive pharyngeal pH probe to detect pharyngeal acid including aerosolized acid (Restech Dx-pH probe)</li>
<li style="margin-left: 0px;"><strong>NOT specific</strong> → cannot detect weakly-acidic or nonacidic reflux</li>
<li style="margin-left: 0px;">Has <strong>poor concordance</strong> with traditional pH-impedance monitoring</li>
<li style="margin-left: 0px;">Does NOT correlate with clinical outcomes</li>
<li style="margin-left: 0px;">Panel agreed: <strong>oropharyngeal pH monitoring alone has poor specificity for LPRD</strong> in patients with LPS → NOT supported as stand-alone tool</li>
</ul>
</div></details>
<details><summary><strong>8.6 Summary Table for Diagnostic Tools</strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Diagnostic Tool</th>
<th>Confirmatory for GERD/LPRD</th>
<th>Supportive of GERD/LPRD</th>
<th>Exclusionary</th>
</tr></thead>
<tbody>
<tr>
<td>Laryngoscopy</td>
<td>None</td>
<td>None</td>
<td>Not diagnostic for LPRD</td>
</tr>
<tr>
<td>Upper GI Endoscopy</td>
<td>LA B/C/D esophagitis, biopsy-proven Barrett&#x27;s, peptic stricture, hiatal hernia</td>
<td>Disrupted EGJ</td>
<td>Inlet patch not diagnostic</td>
</tr>
<tr>
<td>pH-impedance</td>
<td>AET &gt;6.0%, &gt;80 distal events, &gt;10 hypopharyngeal events on HEMII-pH</td>
<td>Positive symptom-reflux association, low mean-nocturnal baseline impedance</td>
<td>AET &lt;4.0%</td>
</tr>
<tr>
<td>Wireless pH (96-hr)</td>
<td>AET &gt;6.0% on 2+ days</td>
<td>AET &gt;4.0% on 1+ day</td>
<td>AET &lt;4.0% on all 4 days</td>
</tr>
<tr>
<td>Oropharyngeal pH (Restech)</td>
<td>None</td>
<td>None</td>
<td>Not diagnostic</td>
</tr>
</tbody>
</table>
</div></details>
</div></details>
<details><summary><strong>9. Laryngeal Hyperresponse and Hypervigilance</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>9.1 Conceptual Framework</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">The larynx is critical intersection of <strong>breathing, communication, and swallowing</strong></li>
<li style="margin-left: 0px;">These processes can become measurably disrupted with pathologic reflux, stress, vagal sensitivity, and sequelae from medical comorbidities</li>
<li style="margin-left: 0px;">Term <strong>&quot;laryngoresponders&quot;</strong> first coined by Aronson in 1990 → describes predisposition (by physical makeup or personality) to manifest emotional distress through sensory changes in larynx or voice</li>
<li style="margin-left: 0px;">Survey of 1,217 adults: <strong>16%–46%</strong> of general population self-identifies as laryngoresponders</li>
</ul>
</div></details>
<details><summary><strong>9.2 Laryngeal Hyperresponse</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Manifests as repetitive laryngeal behaviors such as <strong>throat clearing or coughing, breath-holding</strong>, or biomechanical strain at vocal folds</li>
<li style="margin-left: 0px;">Can alter voice quality or cause globus sensation</li>
<li style="margin-left: 0px;">May contribute to or be primary etiology of LPS with or without true LPRD</li>
</ul>
</div></details>
<details><summary><strong>9.3 Laryngeal Hypervigilance</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Definition</strong>: increased threat-induced attention to the larynx</li>
<li style="margin-left: 0px;">Often coexists with symptom-specific anxiety, fear/worry about LPS and perceived consequences</li>
<li style="margin-left: 0px;">Psychological processes that can influence LPS</li>
</ul>
</div></details>
<details><summary><strong>9.4 Symptom-Specific Anxiety</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Fear/worry about LPS and perceived consequences</li>
<li style="margin-left: 0px;">Can contribute to or be primary etiology of LPS with and without pathologic reflux</li>
</ul>
</div></details>
<details><summary><strong>9.5 Psychological Contribution</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">People may be predisposed to manifest emotional distress through their larynx → may contribute to or be primary etiology of LPS</li>
<li style="margin-left: 0px;">Both general psychological processes (e.g., depression) and symptom-specific cognitive/behavioral processes (e.g., laryngeal hypervigilance, symptom-specific anxiety) can contribute to LPS symptom perception</li>
<li style="margin-left: 0px;">Patients with LPS and typical esophageal symptoms may report increased psychological symptoms such as <strong>depression, hypervigilance, and/or symptom-specific anxiety</strong></li>
</ul>
</div></details>
<details><summary><strong>9.6 The Laryngeal Cognitive-Affective Tool (LCAT)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Validated patient-reported outcome (PRO) instrument</li>
<li style="margin-left: 0px;">Helps distinguish candidates with elevated levels of hypervigilance and anxiety related to LPS</li>
<li style="margin-left: 0px;">Identifies individuals who may improve with behavioral intervention</li>
</ul>
</div></details>
<details><summary><strong>9.7 Clinical Implications</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Patients with LPS being evaluated for LPRD who have <strong>negative reflux monitoring studies</strong> and <strong>nonresponse to trial of acid reducing therapy</strong> should be considered for:</li>
<li style="margin-left: 20px;">Disorder of brain-larynx interaction</li>
<li style="margin-left: 20px;">Hypervigilance</li>
<li style="margin-left: 20px;">Nongastrointestinal process</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>10. Laryngeal Behavioral Therapy</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>10.1 Role of Speech-Language Pathologists (SLPs)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">SLPs specializing in voice and upper airway disorders offer interventions aimed at modifying dysregulated patterns</li>
<li style="margin-left: 0px;">Use mechanical reorganization and healthful cognitive perspectives associated with LPS</li>
<li style="margin-left: 0px;">Precedent for interventions working in individuals with:</li>
<li style="margin-left: 20px;">Confirmed reflux</li>
<li style="margin-left: 20px;">Isolated cough</li>
<li style="margin-left: 20px;">Inducible laryngeal obstruction/paradoxical vocal fold movement</li>
<li style="margin-left: 20px;">Muscle tension dysphonia</li>
</ul>
</div></details>
<details><summary><strong>10.2 Laryngeal Recalibration Therapy (LRT)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Novel structured approach</strong> that infuses traditional SLP techniques with:</li>
<li style="margin-left: 20px;">Heart rate variability biofeedback</li>
<li style="margin-left: 20px;">Acceptance and commitment therapy (ACT)</li>
<li style="margin-left: 0px;">Addresses perceived and confirmed irritation manifesting as cough, throat-clearing, dyspnea, and voice change</li>
<li style="margin-left: 0px;">Individuals with LPS can undergo initial laryngeal recalibration training provided by <strong>voice-specialized speech-language pathologist</strong></li>
</ul>
</div></details>
<details><summary><strong>10.3 Clinical Application Guidelines</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">If LPS is accompanied by typical reflux symptoms → LRT can follow trial of dietary/lifestyle modification and acid suppression</li>
<li style="margin-left: 0px;">Upon completion of laryngeal recalibration training,</li>
</ul>
</div></details>
<details><summary><strong>10.3 Clinical Application Guidelines (continued)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Patients with ongoing hypervigilance, anxiety, depression, and LPS symptoms may benefit from psychological intervention</li>
<li style="margin-left: 0px;">Behavioral therapies used to address psychological targets (e.g., cognitive behavioral therapy) can be used alone or in combination with other modalities (LRT, neuromodulators, dietary management)</li>
</ul>
</div></details>
<details><summary><strong>10.4 Cognitive Behavioral Therapy</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">If psychological processes continue to affect LPS and/or patients experience incomplete relief after LRT or pharmacologic neuromodulation</li>
<li style="margin-left: 0px;">Targets specific cognitive (e.g., &quot;my symptoms will never get better&quot;), emotional (e.g., fear, worry), physiological (increased autonomic arousal), and behavioral processes (avoidance of foods, laryngeal hypervigilance)</li>
<li style="margin-left: 0px;">NOT designed to address comorbid general mental health disorders</li>
<li style="margin-left: 0px;">Focused on psychological processes specifically affecting LPS</li>
<li style="margin-left: 0px;">Delivered by mental health professional with specialized health psychology training</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>11. Pharmacologic Neuromodulation</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>11.1 Role and Indications</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">May attenuate laryngeal hypersensitivity</li>
<li style="margin-left: 0px;">Consider in:</li>
<li style="margin-left: 20px;">LPRD patients with suboptimal response to antisecretory therapy or SLP intervention</li>
<li style="margin-left: 20px;">Isolated LPS with negative esophageal testing</li>
</ul>
</div></details>
<details><summary><strong>11.2 Evidence Base</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Current clinical evidence for neuromodulators, notably <strong>gabapentin and pregabalin</strong>, focuses primarily on treatment of chronic cough through mediation of vagal hypersensitivity</li>
<li style="margin-left: 0px;">Neuromodulators may improve laryngeal hypersensitivity</li>
</ul>
</div></details>
<details><summary><strong>11.3 Tricyclic Antidepressants (TCAs)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Commonly prescribed for treatment of functional GI disorders</li>
<li style="margin-left: 0px;">May help LPS symptoms but anticholinergic side effects (e.g., xerostomia) should be observed</li>
<li style="margin-left: 0px;">Xerostomia may aggravate LPS</li>
</ul>
</div></details>
<details><summary><strong>11.4 Gabapentin and Pregabalin</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">May be effective adjunct to laryngeal recalibration therapy for LPS, especially cough</li>
<li style="margin-left: 0px;">Delta ligands that have demonstrated value in cough</li>
</ul>
</div></details>
<details><summary><strong>11.5 SSRIs and SNRIs</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Have NOT been studied specifically in LPS</li>
<li style="margin-left: 0px;">Individuals with LPS and clinical anxiety and/or depression may derive benefit</li>
<li style="margin-left: 0px;">Can be considered in individuals who have concomitant anxiety and depression</li>
</ul>
</div></details>
<details><summary><strong>11.6 Clinical Recommendations Summary</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">If individuals with isolated LPS and negative reflux testing experience persistent symptoms after laryngeal recalibration training → pharmacologic neuromodulation may be helpful</li>
<li style="margin-left: 0px;">Neuromodulators and laryngeal recalibration training may be helpful in patients with LPRD and partial or poor response to acid suppression therapy</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>12. Patient-Reported Outcome Instruments and Risk Stratification Tools</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>12.1 GERD-Specific PRO Instruments</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Common instruments (GERDQ, GERD-HRQL) are valuable for assessing severity and treatment response of <strong>esophageal symptoms</strong></li>
<li style="margin-left: 0px;">Have suboptimal diagnostic yield for LPS and LPRD</li>
<li style="margin-left: 0px;">Useful for assessment of esophageal symptom severity and evaluating treatment response but <strong>NOT specific for LPS and LPRD</strong></li>
</ul>
</div></details>
<details><summary><strong>12.2 LPRD-Specific PRO Instruments</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Reflux Symptom Index (RSI)</strong>: symptoms assessed are nonspecific for LPRD but can be used to follow many laryngological complaints over time</li>
<li style="margin-left: 0px;">RSI cutoff previously considered clinically significant (≥13) could NOT distinguish patients with increased proximal/pharyngeal reflux or significant symptom correlation on HEMII-pH testing</li>
<li style="margin-left: 0px;"><strong>Reflux Symptom Score (RSS)</strong>: developed in conjunction with HEMII-pH testing; demonstrates higher specificity and sensitivity in predicting increased proximal reflux burden and treatment outcomes</li>
<li style="margin-left: 0px;">However, not considered definitively diagnostic of LPRD based on current evidence by the panel</li>
<li style="margin-left: 0px;"><strong>LPR-HRQL</strong>: not specific for diagnosing LPRD</li>
</ul>
</div></details>
<details><summary><strong>12.3 General Voice and Cough Instruments</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Voice Handicap Index-10 (VHI)</li>
<li style="margin-left: 0px;">Leicester Cough Questionnaire (LCQ)</li>
<li style="margin-left: 0px;">Cough Severity Index (CSI)</li>
<li style="margin-left: 0px;">Value unclear in diagnosing LPRD → should only be used as prescribed PROs, NOT diagnostic instruments</li>
</ul>
</div></details>
<details><summary><strong>12.4 Risk Stratification Tools</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>HAS-BEER</strong>: developed to help direct initial diagnostic and management strategies in patients with LPS</li>
<li style="margin-left: 0px;"><strong>COuGH ReFlX</strong>: validated clinical score to predict GERD in patients with chronic laryngeal symptoms</li>
<li style="margin-left: 0px;">Hold promise in aiding clinicians by classifying patients into risk categories for LPRD based on clinical and demographic factors</li>
<li style="margin-left: 0px;">More data needed before full adoption in consensus algorithm for LPS/LPRD</li>
<li style="margin-left: 0px;">Further validation of these scores for treatment outcomes and in diverse populations represents important future research</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>13. The San Diego Consensus Paradigm: Clinical Application</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>13.1 Initial Evaluation Framework</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Patients meeting definition for LPS → initial evaluation includes:</li>
<li style="margin-left: 20px;">Considering non-GI causes of symptoms</li>
<li style="margin-left: 20px;">Laryngoscopy to evaluate for nonreflux-related causes of LPS</li>
<li style="margin-left: 20px;">Discerning presence of concomitant esophageal reflux symptoms (heartburn, regurgitation)</li>
</ul>
</div></details>
<details><summary><strong>13.2 LPS with Concomitant Esophageal Reflux Symptoms (Algorithm Left Side)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Personalized lifestyle and empiric trials of acid suppression appropriate</li>
<li style="margin-left: 0px;">Symptom assessment at 3 months</li>
<li style="margin-left: 0px;">Those with esophageal symptom and LPS response → likely have LPRD → continue management</li>
<li style="margin-left: 0px;">Those with isolated esophageal symptom response may have ongoing LPS with GERD overlap → can continue management, important to consider disordered laryngeal behavioral response</li>
<li style="margin-left: 0px;">For partial or no response of esophageal symptoms or LPS → next step is objective esophageal testing and consideration of disordered laryngeal behavioral response</li>
<li style="margin-left: 0px;">For any patient with LPS and concomitant esophageal reflux symptoms → objective esophageal testing to assess for GERD/LPRD required <strong>before invasive antireflux therapy</strong> (endoscopic or surgical intervention)</li>
<li style="margin-left: 0px;">Also should be considered if long-term antireflux management is planned</li>
</ul>
</div></details>
<details><summary><strong>13.3 Isolated LPS (Algorithm Right Side)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Critical to consider disordered laryngeal behavioral response at outset</li>
<li style="margin-left: 0px;">Suggested to proceed with objective esophageal testing before any antireflux management to personalize management</li>
<li style="margin-left: 0px;">Dashed curved arrow highlights that disordered laryngeal behaviors can coexist/overlap in setting of objective GERD/LPRD and be driver of symptoms</li>
<li style="margin-left: 0px;">If disordered laryngeal behaviors suspected → speech-language pathology-guided behavioral therapy (e.g., LRT), neuromodulation, and/or cognitive behavioral therapy can be trialed</li>
</ul>
</div></details>
<details><summary><strong>13.4 Paradigm of Laryngopharyngeal Symptoms and Disease</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Presence of LPS does NOT equate to LPRD</li>
<li style="margin-left: 0px;">More commonly, patients with LPS have no objective evidence of reflux → evaluation should focus on nongastrointestinal causes including brain-larynx interaction</li>
<li style="margin-left: 0px;">For patients with objective evidence of LPRD → therapeutic constructs include antireflux management and therapy focused on laryngeal behavioral responses</li>
<li style="margin-left: 0px;">Laryngeal involvement does NOT implicate mental health disorder; symbiotic relationship exists between various stressors and laryngeal hyperresponsiveness independent of diagnosed disorder of affect</li>
</ul>
</div></details>
<details><summary><strong>13.5 Laryngeal Behavioral Response Model</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Cyclical relationship between:</li>
<li style="margin-left: 20px;"><strong>Laryngeal hypersensitivity</strong></li>
<li style="margin-left: 20px;"><strong>Laryngeal hyperresponse</strong></li>
<li style="margin-left: 20px;"><strong>Laryngeal hypervigilance</strong></li>
<li style="margin-left: 0px;">Can contribute to or drive LPS burden</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>14. Mechanisms of Laryngopharyngeal Reflux</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>14.1 Pathophysiological Mechanisms</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Physiological mechanisms underlying LPR often unclear</li>
<li style="margin-left: 0px;">Simplistically: reflux of gastric contents to upper aerodigestive tract implies incompetence of both lower and upper esophageal sphincters</li>
<li style="margin-left: 0px;">Several potential mechanisms for LPR giving rise to symptoms:</li>
<li style="margin-left: 20px;"><strong>Neurogenic</strong></li>
<li style="margin-left: 20px;"><strong>Inflammatory</strong></li>
<li style="margin-left: 20px;"><strong>Behavioral</strong></li>
<li style="margin-left: 20px;"><strong>Motility related</strong></li>
</ul>
</div></details>
<details><summary><strong>14.2 Direct vs Indirect Injury</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Hypothesis: injury to larynx and pharynx occurs:</li>
<li style="margin-left: 20px;"><strong>Directly</strong>: through exposure to gastric acid, pepsin, and bile salts</li>
<li style="margin-left: 20px;"><strong>Indirectly</strong>: through repetitive mucosal trauma from vagally mediated or reactive cough and throat clearing</li>
</ul>
</div></details>
<details><summary><strong>14.3 Esophageal Dysfunction Pathways</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">May affect tracheobronchial airway by:</li>
<li style="margin-left: 20px;"><strong>Reflux pathway</strong> (microaspiration)</li>
<li style="margin-left: 20px;"><strong>Reflex pathway</strong> (vagally mediated airway stimulation)</li>
</ul>
</div></details>
<details><summary><strong>14.4 Cognitive-Behavioral Perpetuation</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Heightened cognitive-behavioral responses may perpetuate laryngeal behaviors</li>
</ul>
</div></details>
<details><summary><strong>14.5 Why Traditional Therapies Often Fail</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Traditional antireflux therapies do NOT address varied mechanisms</li>
<li style="margin-left: 0px;">Fewer than <strong>50% of LPS patients</strong> respond to antisecretory therapy</li>
<li style="margin-left: 0px;">Antireflux surgery frequently yields suboptimal outcomes</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>15. Management Recommendations Summary</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>15.1 Antisecretory Therapy</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Type, dose, frequency, and duration vary widely in literature</li>
<li style="margin-left: 0px;">Unit dose PPI (e.g., omeprazole 20 mg) up to <strong>twice daily for 3 months</strong> recommended for LPS response</li>
<li style="margin-left: 0px;">Novel class: <strong>potassium competitive acid blockers</strong> → approved for reflux-driven conditions including nonerosive reflux disease and erosive esophagitis; could be used in place of PPI therapy</li>
</ul>
</div></details>
<details><summary><strong>15.2 Alginate Therapies</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Inexpensive, generally well-tolerated</li>
<li style="margin-left: 0px;">May reduce patient perception of globus</li>
<li style="margin-left: 0px;">May offer increased benefit compared with PPI monotherapy</li>
</ul>
</div></details>
<details><summary><strong>15.3 Lifestyle Modifications for Managing GERD</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Reduction of intragastric pressure</strong>: weight loss/management, avoiding tight fitting clothing around abdomen</li>
<li style="margin-left: 0px;"><strong>Minimizing postprandial reflux</strong>: maintaining upright posture, avoiding recumbency 2–3 hours after meals, practicing diaphragmatic breathing</li>
<li style="margin-left: 0px;"><strong>Modifying sleeping position</strong> for nocturnal reflux: head of bed elevation, sleeping in left lateral position</li>
<li style="margin-left: 0px;"><strong>Avoiding foods</strong> that trigger symptoms</li>
</ul>
</div></details>
<details><summary><strong>15.4 Personalizing Management</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Recommendations regarding reflux management beyond scope of current initiative</li>
<li style="margin-left: 0px;">Requires consideration of:</li>
<li style="margin-left: 20px;">Available expertise</li>
<li style="margin-left: 20px;">Response to previous treatment trials</li>
</ul>
</div></details>
<details><summary><strong>15.5 When LPS Fails to Respond</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">In case of isolated LPS or when LPS fail to respond to antireflux therapies even in confirmed LPRD</li>
<li style="margin-left: 0px;">Overlap with laryngeal hyperresponsiveness and hypervigilance should be considered</li>
<li style="margin-left: 0px;">Behavioral therapy and/or neuromodulation recommended</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>16. Future Directions and Research Priorities</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>16.1 Validation Needs</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Risk stratification tools (HAS-BEER, COuGH ReFlX) need further validation for:</li>
<li style="margin-left: 20px;">Treatment outcomes</li>
<li style="margin-left: 20px;">Diverse populations</li>
</ul>
</div></details>
<details><summary><strong>16.2 Reflux Event Thresholds</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Identifying clinically relevant reflux episode thresholds requires further research</li>
<li style="margin-left: 0px;">Panel could not reach agreement for thresholds of &gt;80 esophageal reflux events and &gt;10 hypopharyngeal events to be considered abnormal</li>
</ul>
</div></details>
<details><summary><strong>16.3 Inlet Patch</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Further research including controlled studies of ablation impact needed to establish importance of identifying this endoscopic finding in patients with LPS</li>
</ul>
</div></details>
<details><summary><strong>16.4 Potassium Competitive Acid Blockers</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Outcomes research focused on LPS will clarify role in LPR treatment</li>
</ul>
</div></details>
<details><summary><strong>16.5 Baseline Impedance</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Has not been extensively studied in LPS; provides information regarding</li>
</ul>
</div></details>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
